Trial Profile
A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Fenofibrate; HMG-CoA reductase inhibitors
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 30 Aug 2008 New trial record.